MARKET

BNTC

BNTC

Benitec Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.62
+0.77
+9.81%
Opening 14:50 08/10 EDT
OPEN
8.00
PREV CLOSE
7.85
HIGH
9.00
LOW
7.85
VOLUME
67.78K
TURNOVER
--
52 WEEK HIGH
19.80
52 WEEK LOW
4.140
MARKET CAP
13.85M
P/E (TTM)
-227.4406
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BNTC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.

EPS

BNTC News

More
3 Cheap Stocks for the Short-Term Investor
GuruFocus News · 07/30 13:59
Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study
PR Newswire · 07/08 13:00
Benitec Biopharma Initiates BB-301 Transduction Study In Large Animal Subjects
Benzinga · 07/08 12:07
IVR, NVAX, SRG and EXEL among midday movers
Seeking Alpha - Article · 04/20 16:40
Should You Be Concerned About Benitec Biopharma Limited's (NASDAQ:BNTC) Historical Volatility?
Simply Wall St. · 04/20 11:49
Wells and BMO cut views on Gilead in premarket analyst action
Seeking Alpha - Article · 04/20 11:05
Benitec Biopharma Announces the Completion of Redomiciliation to the United States
PR Newswire · 04/15 12:52
Benitec Biopharma Appoints Edward Smith to the Board of Directors
PR Newswire · 04/15 01:28

Industry

Biotechnology & Medical Research
-0.09%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About BNTC

Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.
More

Webull offers kinds of Benitec Biopharma Inc stock information, including NASDAQ:BNTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNTC stock methods without spending real money on the virtual paper trading platform.